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HLA-G is aHLA-class Ibmoleculewith potent immunomodulatory activities, which is expressed in physiological conditions, where
modulation of the immune response is required to avoid allograft recognition (i.e.,maternal-fetal interface or transplanted patients).
However, HLA-G can be expressed de novo at high levels in several pathological conditions, including solid and hematological
tumors and during microbial or viral infections, leading to the impairment of the immune response against tumor cells or
pathogens, respectively. On the other hand, the loss of HLA-G mediated control of the immune responses may lead to the onset
of autoimmune/inflammatory diseases, caused by an uncontrolled activation of the immune effector cells. Here, we have reviewed
novel findings on HLA-G functions in different physiological and pathological settings, which have been published in the last two
years. These studies further confirmed the important role of this molecule in the modulation of the immune system.
Dedicated to the memory of Professor Olavio Roberto Baricordi for his creative and groundbreaking work in the study of
HLA-G implication in physiological and pathological conditions
1. Introduction
HLA-G is an important molecule with immunomodulatory
properties, which belongs to “nonclassical” HLA-class Ib
molecules, along with HLA-E, -F, and -H [1]. In contrast
with “classical” HLA-class Ia molecules (HLA-A, -B, and
-C), which are highly polymorphic, with a high number of
alleles encoding a high number of functional proteins, HLA-
Ib molecules display a very low polymorphism, with a small
number of alleles encoding a limited number of proteins.
Similarly to HLA-Ia molecules, also HLA-Ib molecules can
bind peptides generated through a proteasome-driven degra-
dation of cytosolic proteins and present them to specific
subpopulations of CD8+ T cells [2]. However, the main
function of these molecules is to modulate the immune
responses in both physiological and pathological conditions
[3].
HLA-G molecule can be present in seven different iso-
forms encoded through alternative splicing of the same pri-
mary transcript. Membrane-bound isoforms (HLA-G1, -G2,
-G3, and -G4) lack intron-4, which is retained in the soluble
(s) isoforms (HLA-G5, -G6, and -G7), leading to the splicing
of the transmembrane domain. In addition, sHLA-G1, which
is structurally identical to sHLA-G5, can be generated by
shedding of membrane-bound HLA-G1 isoform through
metalloproteases-mediated cleavage [4]. Only HLA-G1 and
-G5 present a full length heavy chain, which is associated
with 𝛽2-microglobulin and binds small peptides, although
it is unclear whether or not HLA-G can present them
to CD8+ T lymphocytes [5]. In this respect, Diehl et al. have
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characterized specific motifs in HLA-G restricted peptides
and they have concluded that HLA-G can present peptides
similarly to classical HLA-class I molecules [6].
HLA-G can interact with immunoglobulin-like transcript
2 (ILT2), which is expressed by T and B lymphocytes, Natural
Killer (NK) cells, monocytes/macrophages, and dendritic
cells, and with ILT4, which is expressed only by myeloid
cells (i.e., dendritic cells, monocytes, and macrophages and
neutrophils) [7]. In addition, HLA-G can interact with
KIR2DL4 expressed by NK cells [8] and CD160 expressed
by T lymphocytes, NK cells, and endothelial cells [4]. Upon
interaction with these receptors, HLA-G can affect the func-
tion of different cell populations. In particular, HLA-G (i)
impairs T cell function, by inhibiting proliferation [9] and
cytotoxicity [10] and by inducing apoptosis [11] and expan-
sion of regulatory T cells [12, 13], (ii) inhibits differentiation,
proliferation, and cytokine production in B lymphocytes
[14], (iii) inhibits proliferation and cytotoxicity [15, 16] of
peripheral blood NK cells and induces proliferation and
release of proangiogenic factors in blood and uterineNK cells
[17–19], (iv) inhibits chemotaxis of different T, B, and NK cell
populations by downregulating chemokine receptors expres-
sion on their surface [20], (v) inhibits phagocytosis and pro-
duction of reactive oxygen species in neutrophils [7], and (vi)
dampens angiogenesis, by inhibiting endothelial cells prolif-
eration [21].
In the last years, several papers have demonstrated that
HLA-G can be present as a homodimeric molecule, which
is generated through a disulfide bond [22–24]. Moreover, it
has been observed that homodimer ismore biologically active
than the monomeric form [13, 25, 26].
2. HLA-G and Cancer
Overexpression of membrane-bound soluble and sHLA-G
has been detected in different human solid and hematological
tumors and might represent a mechanism performed by
tumor cells to escape from the control of the immune system,
by inhibiting NK and T cells mediated lysis [4].
In the last two years, several papers have addressed the
role of HLA-G in tumor progression or have characterized
this molecule as prognostic factor for the clinical outcome of
cancer patients (Table 1).
Loumagne et al. have performed an interesting study
using a murine model. In fact, HLA-G can interact with
murine paired immunoglobulin-like receptor- (PIR-) B,
ortholog of human ILT receptors, thus enabling the investiga-
tion of its role in vivo. Immunocompetent mice were injected
either with syngeneic tumor cells coexpressing human HLA-
G5 and 𝛽2-microglubulin (h𝛽2m) or with h𝛽2m+ HLA-G5−
tumor cells. Interestingly, h𝛽2m+ HLA-G5− tumors were
rejected, whereas h𝛽2m+ HLA-G5+ tumors secreted soluble
HLA-G, which protected them from h𝛽2m-elicited immune
rejection, and grew similarly to a poorly immunogenic
tumor. They demonstrated that HLA-G5 tumor expression
dampened anti-h𝛽2m B cell response through accumulation
of myeloid-derived suppressor cells which inhibited T cell
proliferation and reduced T and B cell tumor infiltrate [27].
Zheng et al. have demonstrated that HLA-G (mostly
HLA-G1 and -G5) is expressed by tumor lesions in esophageal
squamous cell carcinoma (ESCC) patients, but not in adjacent
normal tissues or in healthy controls. Moreover, such expres-
sion positively correlated with lymph node metastasis and
cancer cell differentiation. Accordingly, sHLA-G serum levels
were higher in patients than in controls [28].
An interesting study has been performed by Reimers
and colleagues on rectal cancer patients. They analyzed
tumors by tissue microarray for the presence of Foxp3+ cells
(Tregs) and tumor expression of HLA-E and HLA-G. They
observed that patients with rectal tumors characterized by
loss of HLA class I expression, Foxp3+ infiltration below
median, and weak HLA-G expression displayed a worse
overall survival (OS) and disease-free survival (DFS) [29]. In
contrast, Guo et al. have demonstrated that the majority of
colorectal cancer tissues tested positive for HLA-G or HLA-
E expression, and half of them expressed both molecules.
Moreover, expression levels of HLA-G or HLA-E and the
combined expression of both molecules were all negatively
correlated with OS of colorectal cancer patients. However,
these authors found that only HLA-G expression can serve as
independent factor for OS, whereas the expression of HLA-
E was significantly correlated with tumor metastasis [30].
Yan et al. have analyzed the expression of soluble HLA-
G5/G6molecules in tumor samples from non-small-cell lung
cancer (NSCLC) patients, using specific mAb 5A6G7. sHLA-
G expression was observed in half of NSCLC lesions and
was significantly higher in adenocarcinoma lesions than that
in squamous cell carcinoma and adenosquamous carcinoma
lesions.The authors concluded that sHLA-G could be a useful
biomarker to discriminate adenocarcinoma from squamous
cell carcinoma in NSCLC patients [31].
Another interesting study comes fromXu and colleagues.
They analyzed HLA-G expression in a cohort of patients with
pancreatic carcinoma and found high levels of HLA-G in
the majority of tumor samples. Moreover, they demonstrated
that HLA-G levels represented an independent predictor for
patients’ OS, and a positive correlation was found between
HLA-G expression and tumor stage, extrapancreatic infil-
tration, lymph node involvement, and poor differentiation.
Finally, they demonstrated that plasma levels of sHLA-Gwere
higher in patients than in healthy controls, and sHLA-G levels
inversely correlated to numbers of peripheral activated T
cells, thus suggesting that sHLA-G promotes tumor immune
escape through the inactivation T cell responses [32].
A study performed byWang et al. described a relationship
between HLA-G expression and the sharpness of low-grade
glioma tumor borders in magnetic resonance images. In
particular, high HLA-G expression was detected in larger
tumors with blurred boundaries, which may be those prone
to diffuse invasion. Therefore, patients with tumors that
highly expressed HLA-G were less likely to have undergone
complete resections [33].
Expression and function of HLA-G and regulatory
microRNA (miR-152, -148A, -148B, and -133A) have been
analyzed by Jasinski-Bergner and colleagues in renal cell
carcinoma (RCC).They have observed an inverse correlation
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Table 1: Novel findings on HLA-G and tumors.
Type of tumor Observation Correlation with clinicaloutcome PB sHLA-G Author
Murine model HLA-G
+ tumors are protected from
rejection — — Loumagne et al. [27]
ESCC Tumors but not adjacent tissuesexpressed HLA-G
Positive correlation with
metastasis Increased Zheng et al. [28]
Rectal cancer Tumors are HLA-G
+, FOXP3+, and
HLA-class I− Worse OS — Reimers et al. [29]
Colorectal cancer Most tumors expressed HLA-Gand/or HLA-E Worse OS — Guo et al. [30]
NSCLC
HLA-G is expressed in
adenocarcinoma but not in
squamous cell carcinoma
— — Yan et al. [31]
Pancreatic cancer Most tumors are HLA-G+ Positive correlation withmetastasis and worse OS Increased Xu et al. [32]
Glioma HLA-G expression is higher intumors with blurred boundaries
Positive correlation with
invasiveness — Wang et al. [33]
Renal cell carcinoma
Expression of some miRNAs
downregulates HLA-G expression
and increased antitumor immune
response
— — Jasinki-Bergner et al.[34]
Gastric cancer TGF-𝛽 induced HLA-G expressionthrough miR152 downregulation — — Guan et al. [35]
Gastric cancer HLA-G
+ DC-10 cells are increased
in PB of patients Worse prognosis Increased Xu et al. [36]
Murine model LILRB1
− NK cells are more effective
against HLA-G+ tumors — — Wu et al. [37]
Pancreatic cancer CD3
+ TIL are decreased in HLA-G+
tumors Worse OS — Zhou et al. [38]
Breast cancer
Opposite prognostic value of free
sHLA-G and sHLA-G in MV after
chemotherapy
sHLA-G in MV positively
correlated with worse prognosis;
free sHLA-G positively
correlated with better outcome
— Ko¨nig et al. [39]
Breast cancer
Higher sHLA-G levels in patients
without previous pregnancy and
breastfeeding history
Worse OS Increased Zidi et al. [40]
DLBCL Different prognostic value of del/delpolymorphisms of HLA-G gene Worse OS — Bielska et al. [41]
NSCLC
SNP in HLA-G and LILRB1 genes
and expression of HLA-G and
LILRB1 are related to clinical
outcome
Positive correlation to high risk
of tumor and tumor stage — Wis´niewski et al. [42]
Prostate cancer
Polymorphisms in 3󸀠 UTR of
HLA-G gene are related to clinical
outcome
Positive correlation to higher
susceptibility — Zambra et al. [43]
Gastric adenocarcinoma
Higher frequency of some
polymorphisms of HLA-G gene in
healthy controls than in patients
— — Khorrami et al. [44]
CLL
14 bp polymorphism in 3󸀠 UTR of
HLA-G gene is related to clinical
outcome
Worse OS — Rizzo et al. [45]
between the expression of miR-148A and -133A and HLA-
G protein in situ and in vitro. They concluded that a stable
miRNA overexpression downregulated HLA-G expression,
thus enhancing NK and LAK mediated cytotoxicity. This
hypothesis has been confirmed by the analysis of immune
cell infiltration [82]. They have also identified two additional
miRNAs (miR-548q and miR-628-5p) which may regulate
HLA-G expression in RCC, demonstrating a direct interac-
tion of these miRNAs with the 3󸀠 untranslated region (3󸀠
UTR) of HLA-G. Stable overexpression of miR-548q and
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miR-628-5p caused a downregulation of HLA-G mRNA and
protein, leading to an enhanced NK cell-mediated cytotox-
icity. In addition, they found an inverse correlation between
the expression of miR-628-5p andHLA-G protein in primary
RCC lesions and cell lines. The authors concluded that these
miRNAs, which are able to tune HLA-G expression, might
serve as future therapeutic targets [34]. The interactions
between HLA-G and miR-152 (and TGF-𝛽) have been also
analyzed by Guan and colleagues in gastric cancer (GC).
They observed a positive correlation between serum levels
of TGF-𝛽 and HLA-G in GC patients and a direct TGF-𝛽-
mediated induction of HLA-G expression in GC cell lines in
vitro. Furthermore, TGF-𝛽 also inhibitedmiR-152 expression,
and HLA-G was posttranscriptionally regulated by miR-152.
In addition,miR-152 overexpression repressedHLA-Gupreg-
ulation induced by TGF-𝛽. Finally, the authors observed that
miR-152 expression levels were inversely correlated to both
HLA-G and TGF-𝛽 levels in GC patients. They suggested
a potential application of miR-152 as therapeutic target or
potential biomarker for GC patients [35]. Also the study
carried out by Xu et al. has focused on HLA-G expression
in GC. The authors demonstrated that (i) human tolerogenic
dendritic cellsDC-10, which expressHLA-G, are dramatically
increased in the peripheral blood of GC patients as compared
to healthy donors, (ii) the expression of HLA-G on these
cells is significantly higher than in DC-10 cells from healthy
donors, and (iii) concentration of plasma sHLA-G is higher
in GC patients than controls. Finally, they demonstrated
that these three parameters are worse prognostic factors for
GC patients, thus suggesting an immunosuppressive role for
HLA-G and DC-10 cells in GC [36].
A novel interesting study has been published by Wu et
al., who have characterized the antitumor potential of NK
cells genetically modified to downregulate the expression
of LILRB1. They have demonstrated that LILRB1− NK cells
proliferate upon stimulation signals, migrate, and eliminate
HLA-G− targets cells as parental NK cells do. Moreover,
LILRB1− NK cells exhibit higher proliferation, conjugate
formation, degranulation, and killing activities compared to
parent NK cells in the presence of HLA-G+ target cells.
Finally, LILRB1 silencing rescued NK cell antitumor activity
in a xenograft cancer model [37].
The effect of HLA-G expression by tumor cells on tumor
infiltrating lymphocytes (TIL) has been also addressed by
Zhou et al. in pancreatic cancer (PC). They detected HLA-
G overexpression in tumor samples from PC patients, but
not in nontumor tissues. The number of CD3+ TIL was
significantly lower in HLA-G+ than in HLA-G− tumors.
More importantly, the authors demonstrated that HLA-G
expression and low intratumoral CD3+ staining represent
independent prognostic factors pointing to worse OS of
PC patients. These findings suggest that HLA-G expression
impairs host antitumor immune response and predicts a poor
prognosis in PC [38].
Ko¨nig and colleagues have demonstrated for the first
time that HLA-G might also serve as prognostic marker to
predict the clinical outcome of neoadjuvant chemotherapy
(NACT). In fact, they analyzed total sHLA-G and HLA-
G levels in extracellular vesicles (EV) in plasma samples
from breast cancer (BC) patients, before and after NACT.
They found that total and free sHLA-G levels were higher in
treated patients than in healthy controls. More importantly,
high sHLA-G in EV before NACT positively correlated to
disease progression, whereas free sHLA-G levels were directly
correlated to a better clinical outcome, thus demonstrating
that different sHLA-G subcomponents may have different
prognostic impacts on the clinical outcome of NACT treated
BC patients [39]. Zidi et al. have also focused on HLA-G
function in BC patients. They analyzed sHLA-G in plasma
samples obtained from women with BC and correlated
sHLA-G concentration with pregnancy and breastfeeding
history. They reported significant differences in sHLA-G
levels between BC patients with/without breastfeeding expe-
rience. Interestingly, BC patients without previous pregnancy
experience display higher levels of sHLA-G, and patients
without both pregnancy and breastfeeding history showed
a significant enhancement in tumor size compared with
patients who had both experiences. These data suggested
that a previous pregnancy and breastfeeding experience may
protect against advanced BC stages through reduced levels of
sHLA-G [40].
Five novel and interesting studies have addressed the
correlation of different polymorphism of HLA-G gene with
tumor progression. Bielska et al. have investigated the influ-
ence of two HLA-G polymorphisms, HLA-G-725C/G/T and
HLA-G 14-base pair, on the susceptibility to diffuse large
B-cell lymphoma (DLBCL) and on the clinical course of
the disease. They observed that frequencies of HLA-G-
725GG or HLA-G-725GC genotype were lower, and those
of the HLA-G ins/ins genotype were higher in the patients
compared with controls. Moreover, patients carrying the
HLA-G-725CC genotype presented a better OS than subjects
with other HLA-G-725C/G/T polymorphisms. Patients with
homozygous HLA-G del/del had a worse OS than subjects
carrying the HLA-G del/ins or the HLA-G ins/ins genotype.
On the basis of genotype distribution, authors defined two
HLA-G genotype-based risk groups; a high-risk (HR) group
presented a worse OS than low-risk (LR) patients [41].
Wis´niewski et al. have characterized several polymorphisms,
three in HLA-G gene (-964A>G, -725C>G>T, and -716T>G
in the promoter and a 14 bp ins/del in the 3󸀠UTR), five
in LILRB1 gene (-5651G>A in intron 14, 5717C>T L622L,
5724G>A E625K, 5774 C>A P641P in exon 15, and 5806C>T
in 3󸀠UTR), and 9620 9A/10A polymorphisms in exon 7
of KIR2DL gene in NSCLC patients. They have observed
that only one single nucleotide polymorphism (SNP) in
HLA-G (-964A>G) and one in LILRB1 (5724G>A) posi-
tively correlated with a higher risk of NSCLC. In addition,
5724G>A in LILRB1 gene was associated with protection
from tumor cell infiltration of regional lymph nodes. Finally,
tumor tissue samples tested positive for HLA-G and LILRB1
protein expression, and those expression levels significantly
correlated with tumor stage [42].
Zambra et al. have evaluated the impact of eight poly-
morphisms in the 3󸀠UTR region on susceptibility to the
development of prostate cancer (PCa). They identified the
UTR-4 haplotype as a risk factor to PCa. Furthermore,
the “non-14 bp Ins +3142G +3187A” haplotype, the +3003CT
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genotype, and the +3003C allele are also related to a higher
susceptibility to PCa. They conclude that HLA-G 3󸀠UTR
polymorphism has a great influence on PCa susceptibility
[43].
Khorrami and colleagues investigated whether HLA-G
polymorphisms might serve as a potential risk factor for
clinical outcomes in gastric adenocarcinoma (GAC). They
found that G∗01:01:03:01 and G∗01:01:08 allele distributions
are significantly higher in healthy controls than in GAC
patients and seem to have protective effect. Moreover, the
G∗01:01:03:01/G∗01:04:01 andG∗01:01:02:01/G∗01:01:08 geno-
types frequencies are higher in healthy controls than in
patients. They conclude that HLA-G gene polymorphisms
could affect GAC induction and its outcome [83].
In this line, Rizzo and coauthors showed the prognos-
tic value of the 14-base pair deletion (del) polymorphism
(rs66554220) in the 3󸀠 untranslated region of HLA-G, with
del/del patients showing reduced overall survival of patients
with chronic lymphocytic leukemia, as compared to those
with other genotypes [45].
In summary, novel findings in the last two years con-
firmed that the expression of HLA-G is generally detected
in tumors but not in normal tissues, and such expression
positively correlated with tumor progression, metastasis,
invasiveness, and worse prognosis of patients. The role of
HLA-G (through the interaction with LILRB1) in the control
of antitumor immune response has also been confirmed both
in cancer patients and in murine models of human tumors.
Finally, several polymorphisms of HLA-G and LILRB1 genes
have been characterized in the last two years, with positive
or negative correlation with tumor stage and susceptibility
of patients to develop tumors of patients’ survival, thus
confirming the important role of HLA-G in tumorigenesis
and tumor progression.
3. HLA-G and Pregnancy
The important role of HLA-G in human pregnancy has
been fully characterized in the last years. Different HLA-G
isoforms are expressed by trophoblast cells at maternal-fetal
interface. HLA-G expressed and released by trophoblast cells
can interact with cellular receptors expressed by immune
(T cells, NK cells, macrophages, and dendritic cells) and
nonimmune (endothelial cells) cells present in the decidua,
triggering either inhibitory or activating signals. Such inter-
actions allow us to (i) limit maternal immune response
against semiallogeneic fetal tissues by impairment of decidual
NK cell cytotoxicity, T and B cell proliferation, and induc-
tion of apoptosis of activated CD8+ T cells, (ii) stimulate
placental development through secretion of proangiogenic
factors by decidual (d) NK cells and macrophages, and
(iii) provide a protective effect for pregnancy outcome by
stimulating IL-4 secretion by CD4+ T cells [84]. In this
view, some novel interesting data have been obtained by
Tilburgs and coworkers, who have isolated and characterized
invading HLA-G+ extravillous trophoblasts (EVT) cells and
HLA-G− villous trophoblasts (VT). Using microarray and
functional gene set enrichment analysis, they revealed a
striking immune-activating potential for EVT, which was
absent in VT. Moreover, they performed cocultures of HLA-
G+ EVT cells with matched decidual immune cells, and
they found that EVT induced differentiation of CD4+ T
cells in CD4+CD25hiFOXP3+CD45RA+ regulatory T cells
(Treg) and increased the expression of FOXP3 in these cells.
Moreover, EVT did not enhance cytokine secretion in dNK
(whereas stimulation of dNK with other stimuli confirmed
the distinct cytokine secretion profiles of dNK compared to
peripheral bloodNK cells) [13].The interaction between dNK
and EVT at the maternal-fetal interface was further charac-
terized in a second study, where the authors demonstrated
that dNK interacts with filamentous projections from EVT
enriched in HLA-G, which may represent the initial stage
of synapse formation. Moreover, dNK in this area expressed
HLA-G on the surface or in the cytoplasm. Activation of dNK
downregulated HLA-G expression and restored cytotoxicity,
whereas HLA-G expression was reacquired by incubation
with EVT. These data suggested that HLA-G undergoes a
cycle of trogocytosis, endocytosis, degradation, and finally
reacquisition on dNK, upon interaction with EVT. However,
dNK can be activated by cytokines and/or viral products to
acquire the ability to control virus infection at the interface
(i.e., in the presence of human cytomegalo virus-infected
decidual stromal cells) [46]. Collectively, all these data con-
firmed that HLA-G+ EVT cells have unique properties in
maternal-fetal tolerance establishment.
Immune cells in the decidual compartment have been
further characterized by Djurisic et al., who have analyzed
sHLA-G and cells from placental bed and peripheral blood
in first trimester. They found an increased number of T
cells with low CD4 or CD8 expression in the placental
bed. Soluble HLA-G was increased in “uterine blood” as
compared to peripheral blood. Moreover, KIR2DL4 and
LILRB1 expression was upregulated on uterine NK cells.
Finally, a correlation was found between uterine sHLA-G
and the fraction of KIR2DL4+ uterine NK cells. The authors
hypothesize that the phenotype of uterine NK cells may be
influenced by HLA-G on trophoblast cells and by sHLA-G in
the uterus [47].
Ferreira and coworkers have performed an interesting
study to analyze the genetic regulation of HLA-G expression
in the placenta. They found a novel cis-regulatory enhancer
element 12 kb upstream of HLA-G gene (Enhancer L). More
importantly, deletion of this enhancer ablatedHLA-G expres-
sion in JEG3 cells and in primary human trophoblast cells iso-
lated from placenta. They demonstrated that this enhancer is
cell-type specific and containsmotifs for transcription factors
of CEBP and GATA (which are essential for placentation),
thus suggesting that these factors may also control HLA-G
expression on trophoblast [48].
In the last two years, some studies have addressed
interesting novel aspects of the role of HLA-G in pregnancy
(Table 2). Klitkou et al. have performed the first large study
simultaneously measuring sHLA-G in both maternal and
umbilical cord blood to test whether there is a correlation
between sHLA-G levels in maternal and fetal blood. There-
fore, they havemeasured the levels of sHLA-G1/-G5 inmater-
nal blood and paired umbilical cord blood samples from
gestational week 20 (GW20) and at term. Soluble HLA-G
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Table 2: Novel findings on HLA-G and pregnancy.
Observation Correlation with outcomeof pregnancy Author
HLA-G+ EVT but not HLA-G− VT have immune activating
potential and induce Tregs — Tilburgs et al. [13]
dNK acquired HLA-G through interaction with EVT and can be
reactivated by cytokine stimulation — Tilburgs et al. [46]
High HLA-G levels in placental bed correlated with high
expression of KIR2DL4 and LILRB1 on dNK cells — Djurisic et al. [47]
Enhancer L on HLA-G gene is controlled by CEBP and GATA
that are also essential for placentation — Ferreira et al. [48]
sHLA-G is higher in maternal blood at GW20 than at term and
higher in maternal blood than in umbilical blood — Klitkou et al. [49]
Higher 14 bp alleles in fetus are related to higher sHLA-G in
maternal blood at term — Dahl et al. [50]
sHLA-G in seminal plasma is related to 14 bp ins/del genotype
and can predict the success of ART
Positive correlation with
the success of ART Dahl et al. [51]
Higher frequency of 14 bp ins alleles in HLA-G gene is related to
the outcome of pregnancy
Positive correlation with
RIF Lashley et al. [52]
Higher sHLA-G and frequency of KIR2DL4+ NK cells in
uterine flushing samples from secondary infertile women than
in primary infertile woman
Negative correlation with
infertility Rizzo et al. [53]
SNP in 3󸀠 UTR of HLA-G gene is related to outcome of
pregnancy
Positive correlation with
high risk of preeclampsia Quach et al. [54]
SNP in 5󸀠 URR of HLA-G gene is related to outcome of
pregnancy
Positive correlation with
RSA Agrawal et al. [55]
Lower sHLA-G and PAPP-A in women with GDM at third
trimester — Beneventi et al. [56]
Higher sHLA-G in women with preexisting rheumatic disease at
third trimester
Positive correlation with
the success of pregnancy Beneventi et al. [57]
levels were significantly lower in maternal blood at term than
inGW20. At term, sHLA-G levels were significantly higher in
maternal blood than in umbilical blood. They conclude that
sHLA-G is not freely transferred over the placental barrier.
Finally, they found a correlation between HLA-G levels in
maternal blood in GW20 and at term and between HLA-G
levels in maternal blood and umbilical cord blood at term.
This might be due to shared genetic factors which affect
sHLA-G production in mother and child, or it may support
the theory that sHLA-G in the pregnant woman and the fetus
is partly derived from the placenta, which is a shared organ
between mother and child [49]. In this line, Dahl et al. have
correlated HLA-G polymorphisms in the 3󸀠UTR to sHLA-G
levels in maternal blood plasma samples from GW20 and at
term, as well as in fetal umbilical cord blood samples. They
have observed that higher numbers of 14 bp ins alleles in the
fetus were associated with higher maternal sHLA-G levels at
term (restricting the analysis to 14 bp ins/del heterozygous
mothers). Furthermore, they found that increasing numbers
of fetal 14InsG alleles are related to significantly increased
levels of sHLA-G in maternal blood plasma samples at
term in heterozygous 14DelC/14InsGmothers.They conclude
that combined fetomaternal HLA-G genotypes are related to
sHLA-G levels in maternal blood plasma [50].
It has been previously demonstrated that human sem-
inal plasma contains HLA-G [85]. In a novel study,
Dahl et al. found that sHLA-G levels in seminal plasma
samples correlated with HLA-G 14 bp ins/del genotype of
the men, with the del/del genotype showing the highest
level and the ins/ins genotype showing the lowest level of
sHLA-G. Higher seminal plasma levels of sHLA-G were
found in couples where the female partner became pregnant
after assisted reproduction treatments (ART), compared with
couples where no pregnancy was achieved, thus suggesting a
possible role of seminal sHLA-G as an immunomodulatory
factor in the female reproductive tract before and at the time
of conception [51]. The role of HLA-G in the success of in
vitro fertilization (IVF) has been also addressed by Lashley et
al., who have performed genotyping of womenwith recurrent
implantation failure (RIF) and their partners for HLA class I,
HLA class II, HLA-G, andKIR alleles. Results were compared
with those obtained from couples with successful embryo
implantation after their first IVF and normal fertile couples.
They found a higher frequency ofHLA-C2 and 14 bp insertion
in HLA-G in women with RIF than in controls, and they
conclude that these two genetic features represent a risk
factor which may affect the success of IVF [52]. In this view,
Rizzo and coworkers have demonstrated that sHLA-G levels
in uterine flushing samples were lower in primary infertile
women than inwomenwith secondary infertility. In addition,
a lower number of endometrial CD56+KIR2DL4+ NK cells
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were found in primary infertile than in secondary infertile
women [53].
Two additional studies addressed the impact of HLA-
G polymorphisms on the outcome of pregnancy. Quach
and colleagues have addressed the correlation between SNP
in the 3󸀠UTR of the HLA-G gene and an increased risk
of preeclampsia. They found that preeclamptic cases were
associated with a G/G-genotype at SNP +3187. In addition,
one SNP combination (+3027C/C and +3187G/G) was signif-
icantly more prevalent in preeclampsia cases. They hypoth-
esized that HLA-G 3󸀠UTR SNP-pair associations, and not
individual SNPs, could be useful to predict susceptibility to
preeclampsia [54]. In contrast, Agrawal et al. have addressed
the correlation between SNP in the HLA-G 5󸀠-upstream
regulatory region (URR) and recurrent spontaneous abortion
(RSA). They genotyped women with idiopathic RSA (and
their partners) and control couples, and they found an
increased risk for idiopathic RSA in women with mutant
genotypes of -1179G>A, -725C>G/T, and -86A>C SNP. They
observed a 3.5-fold increased risk for -1179G>A and 4.3-fold
increased risk for -725C>G/T SNP among carriers of mutant
parental genotypes in couples who have experienced idio-
pathic RSA. Finally, they demonstrated a downregulation of
HLA-G expression in cases of idiopathic RSA with -1179G>A
and -725C>G/T SNPs. They conclude that these SNP may
affect pregnancy outcome through HLA-G downregulation
[55].
Two interesting studies have been carried out by Ben-
eventi and coworkers on gestational diseases. First, they
analyzed plasma levels of pregnancy-associated plasma pro-
tein A (PAPP-A) and sHLA-G in women with gestational
diabetesmellitus (GDM).They found that womenwithGDM
had significantly lower first-trimester PAPP-A and sHLA-
G concentrations than controls. In addition, sHLA-G levels
increased during gestation in diabetic women, showing an
opposite trend with respect to the controls. They conclude
that PAPP-A and sHLA-G represent independent markers
of GDM, and their variations may help to early unravel the
onset of GDM [56]. In the second study, they analyzed sHLA-
G levels in plasma and cord blood samples from pregnant
women with preexisting rheumatic diseases and unaffected
pregnant women. They found that third-trimester blood
maternal sHLA-G concentrations were significantly higher in
subjects with rheumatic diseases than in controls. Moreover,
cord blood sHLA-G concentrations were significantly higher
in rheumatic disease than in newborns from controlmothers.
In addition, they found a positive correlation between mater-
nal and fetal (i) titers of ANA autoantibodies and (ii) sHLA-
G circulating levels. These data suggested that autoimmune
diseases prompt amaternal and fetal immune responsewhich
favors pregnancy immune tolerance through upregulation of
sHLA-G in maternal and cord blood [57].
Collectively, these novel studies confirmed the important
role of HLA-G expression on EVT in the remodeling of
human deciduas and in the modulation of decidual NK
cell functions. Moreover, recent observations suggested that
maternal and fetal genotype can affect sHLA-G levels in
maternal blood and consequently the success of pregnancy.
Finally, a positive correlation between polymorphisms of
HLA-G gene and infertility, preeclampsia, and abortion has
been further confirmed.
4. HLA-G in Autoimmune/Inflammatory
Diseases
Several studies in the last years have demonstrated that
HLA-G plays an important role in the control of autoim-
mune/inflammatory diseases, such as multiple sclerosis (MS)
[86], Crohn’s disease (CD) [87], psoriasis [88], pemphigus
[89], celiac disease [90], systemic lupus erythematosus (SLE)
[91], asthma [92], juvenile idiopathic arthritis [93], and
rheumatoid arthritis (RA) [94].
Novel data have been obtained by Catamo and cowork-
ers, who have observed that five polymorphisms (namely,
-477 C>G, -369 C>A, 14 bp del/ins, 3187 A>G, and 3196
C>G) and one haplotype (TCGGTACGAAITCCCGAG) of
HLA-G gene were significantly more frequent in celiac
patients than in healthy controls and were correlated with
an increased susceptibility to the disease. Moreover, they
found 5 additional polymorphisms of HLA-G gene (14 bp
I/I, 3187 G/G, 3196 G/G, and 3003 C/C genotypes and
TCGGTACGAAITCCCGAG haplotype) which were associ-
ated with increased disease susceptibility only considering
patients and controls presenting the DQ2.5 or DQ8 HLA-
DQ celiac disease risk haplotypes. These data confirmed that
HLA-G gene polymorphisms correlated to susceptibility to
celiac disease development, suggesting that HLA-Gmolecule
is involved in disease pathogenesis [58]. In another study, the
authors observed that 10 5󸀠URR and 3 3󸀠UTRpolymorphisms
in HLA-G gene and two haplotypes were associated with a
higher risk for RA development, while one polymorphism
in the 5󸀠URR correlated with disease activity. These data
suggested a possible association between HLA-G gene poly-
morphisms and susceptibility to develop RA disease and its
severity [59]. Interestingly, Mariaselvam et al. have observed
that the frequency of +3187A>G HLA-G polymorphism was
higher in rheumatoid factor (RF)+ than in RF− patients, thus
suggesting that this polymorphismmight influence RF status
[60].
In this regard, Veit and coworkers have observed that
homozygosity for the +3142G allele was associated with an
increased risk of RA in Brazil, and the presence of this
allele in homozygosis could be responsible for a low HLA-G
expression profile which favors the development of RA [61].
Moreover, they have also observed that sHLA-G is increased
in RA patients with long-lasting chronic inflammation, and
the percentage of patients showing specific binding of sHLA-
G to LILRB1 was significantly decreased as compared to
controls. Interestingly, RF− patients were significantly over-
represented in the group of patients positive for LILRB1
binding. Furthermore, methotrexate treated patients had
lower LILRB1 binding to sHLA-Gmolecules than nontreated
patients. These results suggested that although increased
levels of sHLA-G are observed, these molecules are not func-
tional against inflammation, due to a low binding capacity
to the receptor, thus highlighting the importance to also
measure the binding capability of sHLA-G to LILRB1 [62].
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Zhang et al. have observed a correlation between HLA-G
14 bp ins/del polymorphism and SLE susceptibility in Asian
and Caucasian subjects [63]. In this line, Favoino et al. have
analyzed serum sHLA-G and the HLA-G gene 14 bp ins/del
polymorphism in patients with systemic sclerosis (SSc).They
subdivided patients on the basis of sHLA-G levels in HLA-
G high and low profile groups, and they detected a higher
disease severity in HLA-G low than in HLA-G high group.
Moreover, they detected a higher frequency of scleroderma
in patients with HLA-G 14 bp del/del. These data suggested
a modulatory effect of sHLA-G on SSc [64]. Similarly, Zidi
and coworkers have observed a correlation between the 14
bp del/ins polymorphism and CD susceptibility in young-
onset (but not in adult-onset) CD patients, concerning the
genotype ins/ins. Moreover, they observed higher sHLA-G
levels in CD patients than in controls, and they found that
patients with 14 bp del/del and 14 bp del/ins genotypes are
the high HLA-G producers. Dimers of sHLA-G were found
in advanced disease stage, thus suggesting a role for sHLA-G
as a prognostic marker for progressive disease in CD patients
[65]. Dimers of sHLA-G have been also analyzed by Fainardi
et al. in MS. They demonstrated that HLA-G dimers in
cerebrospinal fluid weremore frequent inMS patients than in
controls and in magnetic resonance imaging (MRI) inactive
than in MRI active MS patients, thus suggesting that HLA-
G dimers may be implicated in termination of inflammatory
response in MS [66]. Moreover, Mohammadi et al. have
observed that 14 bp insertion in HLA-G could result in lower
plasmaHLA-G levels in patients, and they found a significant
correlation of HLA-G genotype and its plasma levels withMS
susceptibility, thus suggesting a role forHLA-Gas a risk factor
for MS [67].
de Albuquerque and coworkers have analyzed different
polymorphism of 3󸀠UTR of HLA-G gene in type 1 dia-
betes mellitus (T1D) patients. +3001 T allele was observed
only in T1D patients, whereas the +3010 CC genotype and
the UTR-3 haplotype (14 bp del/+3001C/+3003T/+3010C/
+3027C/+3035C/+3142G/+3187A/+3196C), associated with
low and moderate soluble HLA-G expression, respectively,
were underrepresented in patients. They concluded that
a decreased expression of HLA-G in pancreas should be
detrimental in individuals genetically prone to produce less
HLA-G [68].
Two interesting studies have evaluated the correlation
between HLA-G and response to treatment.
Borghi et al. have analyzed the correlation between HLA-
G 14-bp ins/del polymorphism and the response of psoriatic
patients to systemic therapy (acitretin, cyclosporine, or anti-
TNF-𝛼). They found an increased frequency of HLA-G
del allele and del/del genotype in responders only among
patients treated with acitretin, and they proposed this HLA-
G polymorphism as a potential marker of response to
acitretin in psoriatic patients [69]. In contrast, Naidoo et al.
have analyzed the relationship between HLA-G and statins
treatment in patients with asthma. They demonstrated that
statins upregulate mir-148b and -152, and these miRNAs
can affect HLA-G expression. The binding of miRNAs to
HLA-G is modulated by a SNP in the HLA-G 3󸀠UTR that
is associated with asthma risk (rs1063320). Finally, they
observed that individuals with G allele of rs1063320 had
reduced asthma-related exacerbations, thus suggesting that
rs1063320 modifies the effect of statin benefit in asthma by
modulating HLA-G expression through mir-148b and -152
[70].
We can conclude that in the last two years the abil-
ity of HLA-G to limit the progression of autoimmune/
inflammatory diseases has been confirmed. In fact, sHLA-G
levels and several HLA-G polymorphisms have been associ-
ated with higher susceptibility to disease or higher severity
of the disease. Finally, HLA-G has been proposed also as
predictive marker of response to treatment (Table 3).
5. HLA-G in Infectious Diseases
In the last years, the role of HLA-G in the progression
of different infectious diseases has been fully described,
for both microbial and viral infections [95]. Recent stud-
ies have addressed novel aspects of the role of HLA-G
in bacterial infections. Han et al. have demonstrated that
Toxoplasma gondii infection can upregulate sHLA-G release
by trophoblast cells in vitro. Upon coculture with infected
trophoblast cells, dNK cells undergo apoptosis through
upregulation of caspase 3 and caspase 8. They demonstrated
that apoptosis is induced by sHLA-G, since the expression
of caspases is downregulated in the presence of HLA-G
neutralizing antibody. The authors hypothesize that dNK
cells apoptosis may contribute to the abnormal pregnancy
outcomes with T. gondii infection [71].
Sadissou and coworkers firstly analyzed the possible
association between sHLA-G and malaria or malaria related
risk factors in pregnant women. They observed strong corre-
lations between thematernal and cord plasma concentrations
of sHLA-G. Moreover, high cord plasma levels of sHLA-
G were independently associated with low birth weight
and increased risk of P. falciparum infection in infancy.
These results suggested a possible involvement of sHLA-G in
generating immune tolerance during pregnancy-associated
malaria.They concluded that sHLA-Gmay represent a useful
marker of susceptibility to malaria in infants [72].
Bortolotti and coworkers carried out an interesting
study on Pseudomonas aeruginosa, demonstrating that N-(3-
oxododecanoyl)-l-homoserine lactone (3O-C12-HSL) pro-
duced by this bacteria is able to induce HLA-G expression
in human monocytes and T cells, through p38/CREB and
IL-10 induction. These data suggested that HLA-G may be a
mechanism to create a protected niche for bacterial reservoir,
similar to the role ofHLA-Gmolecules during viral infections
[73]. In this line, Rizzo et al. have demonstrated that sHLA-
G plasmatic levels are normalized by antibiotic therapy in
patients with cystic fibrosis and Pseudomonas aeruginosa
infection, thus suggesting a systemic anti-inflammatory role.
However, in the airway system, higher expression of HLA-G
is associated with P. aeruginosa infection. Moreover, CF cell
line and murine model expressed higher HLA-G molecules
in the presence of P. aeruginosa, thus suggesting a role of
HLA-G in reducing systemic inflammation, thus supporting
P. aeruginosa infection [74].
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Table 3: Novel findings on HLA-G in autoimmune/inflammatory disease.
Type of disease Observation Correlation with clinicaloutcome Author
CD Several polymorphisms and one haplotype of HLA-G geneare more frequent in patients than in controls
Positive correlation with
susceptibility Catamo et al. [58]
RA Several polymorphisms and two haplotypes of HLA-G geneare more frequent in patients than in controls
Positive correlation with
susceptibility Catamo et al. [59]
RA Two polymorphisms of HLA-G gene are more frequent inRF+ than in RF− patients
Positive correlation with
disease severity Mariaselvam et al. [60]
RA Homozygosis of 3142G allele is related to lower sHLA-G levels Positive correlation withhigh risk of disease Veit et al. [61]
RA Higher sHLA-G levels in patients with chronic disease andhigher LILRB1 binding in RF− patients
Negative correlation with
disease severity Veit et al. [62]
SLE HLA-G 14 bp ins/del polymorphisms are associated withsusceptibility
Positive correlation with
susceptibility Zhang et al. [63]
SSc Lower levels of sHLA-G in patients than in controls Negative correlation withdisease severity Favoino et al. [64]
CD Higher levels of sHLA-G in patients than in controls Positive correlation withsusceptibility Zidi et al. [65]






Fainardi et al. [66]
MS 14 bp ins in HLA-G gene is related to lower sHLA-G levels Positive correlation withhigh risk of disease Mohammadi et al. [67]
T1D Lower sHLA-G levels in pancreas are detrimental Negative correlation withdisease severity
de Albuquerque et al.
[68]
Psoriasis 14 bp del/del genotype of HLA-G gene is more frequent inpatients responding to therapy
Positive correlation with
response to treatment Borghi et al. [69]
Asthma SNPs in 3
󸀠 UTR of HLA-G gene modulate the binding of
mIRNAs
Positive correlation with
high risk of disease Naidoo et al. [70]
Oliveira Souza and coworkers have detected HLA-G
expression in gastric tissue samples from patients harbouring
H. pylori. Moreover, HLA-G expression was correlated with
milder colonization by H. pylori, milder inflammatory activ-
ity, and location of bacteria in the gastric antrum. This pilot
study explored for the first time HLA-G expression in the
context ofH. pylori infection, but the role of HLA-G remains
to be defined [75].
Two important studies on viral infections have been
carried out. Khorrami et al. have analyzed HLA-G in patients
with Hepatitis C virus (HCV) treated with combined therapy
(IFN-𝛼2𝛼 and ribavirin), to evaluate possible difference
between responder and nonresponder groups. They demon-
strated that HLA-G and IL-10 levels in nonresponder group
were higher than in responder and controls. Additionally,
HLA-G and IL-10 were higher in patients at the beginning
of treatment than in healthy individuals. These findings
suggested that increase of HLA-G and IL-10 in HCV infected
patients might affect the response to combined therapy in
HCV patients [44]. Laaribi and coworkers have analyzed
HLA-G 14 bp ins/del polymorphism at the 3󸀠 UTR of HLA-
G in patients with chronic Hepatitis B virus (HBV) infection,
and they found an association between the 14 bp ins/del poly-
morphism and an enhanced HBV activity, with high HBV
DNA levels. In particular, ins/ins genotype was associated
with a 2.5-fold increased risk of susceptibility to high HBV
replication compared with the del/del and ins/del genotypes.
These results suggest a role for HLA-G polymorphisms as
potential prognostic value for disease outcome evaluation
[76].
In summary, these novel studies confirmed that upreg-
ulation of HLA-G expression and/or release is an immune
escape mechanism performed by virus and bacteria during
infection to avoid the recognition by immune effector cells
and to reduce the inflammatory response. Also in this case,
a predictive role of the success of therapy has been suggested
for HLA-G (Table 4).
6. HLA-G in Transplantation
The important role of HLA-G as a tolerogenic molecule
during allograft transplantation has been extensively char-
acterized. HLA-G expression has been related to a better
acceptance of the allograft, through its ability in shaping an
allogeneic immune response into tolerance [96].
Misra et al. have evaluated the impact of HLA-G allele
associated with UTR-haplotype in end stage renal disease
(ESRD) and acute allograft rejection (AR) cases. The authors
observed an increased risk for G∗01:01:01:03, G∗01:01:02,
G∗01:06, and G∗01:05:N haplotypes, while G∗01:01:01:01 and
G∗01:04:01 haplotypes showed a protective effect in ESRD
and AR cases. Moreover, they found (i) higher levels of
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Table 4: Novel findings on HLA-G and infectious diseases.
Type of disease Observation Correlation with clinicaloutcome Author
Toxoplasmosis Toxoplasma increased the release of sHLA-G by trophoblastinducing apoptosis of dNK cells
Positive correlation with
abnormal pregnancy Han et al. [71]
Malaria Higher sHLA-G levels in cord blood are related to low weightat birth and clinical outcome
Positive correlation with high
risk of infection in infancy Sadissou et al. [72]
Pseudomonas
aeruginosa
P. aeruginosa induced HLA-G expression in monocytes and
T cells protecting from immune response — Bortolotti et al. [73]
Pseudomonas
aeruginosa
sHLA-G levels are decreased during antibiotic therapy in
patients with cystic fibrosis
Negative correlation with
inflammation Rizzo et al. [74]
Helicobacter
pylori




Oliveira Souza et al.
[75]
HCV Higher levels of sHLA-G and IL-10 in patientsnonresponding to therapy with IFN
Negative correlation with
response to therapy Khorrami et al. [44]
HBV Patients with 14 bp ins/ins genotype have higher levels ofHBV activity and HBV DNA copies
Positive correlation with worse
clinical outcome Laaribi et al. [76]
Table 5: Novel findings on HLA-G and transplantation.
Type of transplant Observation Correlation with clinicaloutcome Author
Kidney Higher HLA-G5/G6 levels in ESRD and lower levels ofHLA-G5 in acute rejection
Negative correlation of
HLA-G5 with rejection Misra et al. [77]
Lung Higher levels of sHLA-G in bronchoalveolar lavage frompatients with acute rejection
Positive correlation with high
risk of rejection White et al. [78]
Lung Expression of HLA-G in lung protected from CLAD andassociated with graft acceptance
Positive correlation with graft
acceptance Brugie`re et al. [79]
Lung Two haplotypes of HLA-G gene are associated with lowerlevels of sHLA-G
Positive correlation with
worse long term survival
Di Cristofaro et al.
[80]
Murine model CD4
+HLA-G+ regulatory T cells produce IL-10, sHLA-G,
and IL-35 and ameliorated GvHD — Pankratz et al. [81]
soluble HLA-G5 and -G6 among ESRD cases and (ii) reduced
levels of soluble HLA-G5 and increased levels of membrane-
bound HLA-G1 and -G3 in AR cases. Decreased HLA-G
expression was observed for G∗01:01:01:03 and G∗01:05:N
haplotypes in ESRD and AR cases. These results suggested
that the variation of membrane-bound and soluble HLA-G
isoforms correlated to the risk for ESRD and AR. Moreover,
UTR-haplotypes are involved in different HLA-G expression
patterns [77].
Three recent studies have analyzed the role of HLA-G in
patients who undergo lung transplantation.
White and coworkers have demonstrated that lung solu-
ble HLA-G concentrations were directly related to the pres-
ence of type A rejection but not to lymphocytic bronchiolitis
(the principal complication of lung transplantation). They
found that sHLA-G concentrations in bronchoalveolar lavage
but not in serum positively correlated with the number of
acute rejection episodes in the first 12 months after lung
transplantation and thus may represent a novel marker of
rejection risk [78]. Similarly, Brugie`re et al. have observed that
lung HLA-G expression had a protective effect on chronic
lung allograft dysfunction (CLAD), thus suggesting that early
expression of HLA-G in the graft was positively correlated
with graft acceptance in the long term [79]. An interesting
study carried out by Di Cristofaro and coworkers observed
that the presence of HLA-G∗01:06 UTR2 haplotype was
associated with a worse evolution of cystic fibrosis, but not of
long-term posttransplant survival. In contrast, HLA-G∗01:04
UTR3 haplotype was associated with lower levels of sHLA-
G at day 0 and after three months, impaired long-term
survival, increased CLAD occurrence, and the production of
de novo donor-specific antibodies after three months. This
study firstly observed that different HLA-G haplotypes can
deeply affect clinical outcome of lung transplantation [80].
In the view of the treatment of transplant rejection,
an interesting study comes from Pankratz and cowork-
ers. They compared the features of two subsets of regula-
tory cells, CD4+HLA-G+ cells and CD4+CD25+FoxP3+cells.
They found that both cell populations display alterations
in proximal-signaling pathways upon TCR stimulation and
a hyperpolarization of the plasma membrane when com-
pared to conventional CD4+T cells. CD4+HLA-G+ cells
secreted high levels of IL-10, sHLA-G, and IL-35, while
CD4+CD25+FoxP3+ cells expressed lower levels of these
molecules and exerted their function in a contact-dependent
manner via cAMP.More importantly, they demonstrated that
CD4+HLA-G+ cells ameliorated graft-versus-host disease
in a humanized mouse model, thus suggesting that these
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cells can modulate polyclonal adaptive immune responses in
vivo, representing a promising candidate for future clinical
applications not only in transplanted patients but also for the
treatment of autoimmune/inflammatory diseases [81].
In conclusion, these novel findings confirmed in general
the important role of HLA-G in the acceptance of allograft
and in the prevention of transplant rejection. Moreover,
recent studies suggested a possible clinical application of
CD4+HLA-G+ regulatory T cells in the prevention of GvHD
(Table 5).
7. Conclusions
More than 280 papers on HLA-G have been published in
the last two years confirming the important role of HLA-G
in modulating the function of the immune system. More-
over, novel studies have highlighted the function of HLA-G
gene (and corresponding molecule) as prognostic factor for
patients’ clinical outcome in different pathological settings.
Finally, some authors have unraveled a role for HLA-G as
a predictor of the response to treatments in patients with
tumors or infections.The future goal of the scientific commu-
nity will be to determine and standardize the clinical applica-
tions of HLA-G analysis, in order to introduce this molecule
in the routine tests which might help disease diagnosis and
patients’ follow-up.
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